The OlympiA study showed neoadjuvant olaparib plus durvalumab achieved an 80% pathologic complete response (pCR) rate in patients with T2N0 BRCA-mutated TNBC. This result, superior to what chemotherapy typically accomplishes, suggests a highly effective, chemotherapy-free future for this specific patient subgroup.
Experts question the broad applicability of the Japanese CREATE-X trial, which established capecitabine for residual TNBC. The benefit may be confined to the luminal AR subtype, more common in Asian populations, while being ineffective for the basal-like subtype prevalent in Western patients.
The NAOTRACT trial is pioneering the use of Tumor-Infiltrating Lymphocytes (TILs) as a predictive biomarker. Patients with high TILs receive a less intensive, anthracycline-free neoadjuvant regimen, potentially sparing them from toxicity while maintaining efficacy, representing a major step toward personalized immunotherapy.
Large-scale SEER database analysis shows that patients with T1A and T1B node-negative triple-negative breast cancer had similar outcomes whether they received chemotherapy or were just observed. This challenges the default use of chemotherapy for all patients with very early-stage TNBC.
The podcast reveals a philosophical split among oncologists. One side advocates for universal germline testing to identify all carriers for therapeutic and preventative reasons. The other, more selective approach argues for testing only when the result will directly influence an immediate treatment decision.